Laurent Derré

Publications | Phd and Masters theses

Advanced search is available through Serval

Publications can be managed by accessing Serval via MyUnil


62 publications

2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2004 | 2003 | 2002 | 2001 |
2023
 
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L., Lucca I., Cesson V., Bohner P., Crettenand F., Rodrigues-Dias S.C., Dartiguenave F., Masnada A., Teixeira-Pereira C., Benmerzoug S. et al., 2023/12/14. Journal for immunotherapy of cancer, 11 (12) pp. e008020. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_05D137E31CE9]
Phenotype and Reactivity of Lymphocytes Expanded from Benign Prostate Hyperplasic Tissues and Prostate Cancer.
Ahmed R., Lozano L.E., Anastasio A., Lofek S., Mastelic-Gavillet B., Navarro Rodrigo B., Nguyen S., Dartiguenave F., Rodrigues-Dias S.C., Cesson V. et al., 2023/06/08. Cancers, 15 (12) p. 3114. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4F3B91EA43E2]
 
Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.
Schneider A.K., Domingos-Pereira S., Cesson V., Polak L., Fallon P.G., Zhu J., Roth B., Nardelli-Haefliger D., Derré L., 2023. Frontiers in immunology, 14 p. 1335326. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_4B2B719CC888]
2022
Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.
Domingos-Pereira S., Sathiyanadan K., Polak L., Haefliger J.A., Schmittnaegel M., Ries C.H., Jichlinski P., Roth B., Derré L., Nardelli-Haefliger D., 2022/12/21. International journal of molecular sciences, 24 (1) p. 123. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_0026FCE56475]
Intravesical Ty21a Treatment of Non-muscle-invasive Bladder Cancer Shows a Good Safety Profile.
Lucca I., Derré L., Cesson V., Bohner P., Crettenand F., Rodrigues-Dias S., Dartiguenave F., Masnada A., Texeira-Pereira C., Benmerzoug S. et al., 2022/11. European urology open science, 45 pp. 55-58. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6BF6056A37F5]
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S., Chevalier M.F., Benmerzoug S., Cesson V., Schneider A.K., Rodrigues-Dias S.C., Dartiguenave F., Lucca I., Jichlinski P., Roth B. et al., 2022/08. Journal for immunotherapy of cancer, 10 (8) pp. e004880. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_430EBCEC5757]
 
Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
Benmerzoug S., Chevalier M.F., Verardo M., Nguyen S., Cesson V., Schneider A.K., Dartiguenave F., Rodrigues-Dias S.C., Lucca I., Jichlinski P. et al., 2022/05. European urology focus, 8 (3) pp. 748-751. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_5DF4F82CD6A7]
Identification of Urine Biomarkers to Improve Eligibility for Prostate Biopsy and Detect High-Grade Prostate Cancer.
Alijaj N., Pavlovic B., Martel P., Rakauskas A., Cesson V., Saba K., Hermanns T., Oechslin P., Veit M., Provenzano M. et al., 2022/02/23. Cancers, 14 (5) p. 1135. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_C3E7756D66D6]
2021
Siglec-7 May Limit Natural Killer Cell-mediated Antitumor responses in Bladder Cancer Patients.
Benmerzoug S., Chevalier M.F., Villier L., Nguyen S., Cesson V., Schneider A.K., Dartiguenave F., Rodrigues-Dias S.C., Lucca I., Jichlinski P. et al., 2021/12. European urology open science, 34 pp. 79-82. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_00BEA50EB5F4]
 
Human primed ILCPs support endothelial activation through NF-κB signaling.
Vanoni G., Ercolano G., Candiani S., Rutigliani M., Lanata M., Derré L., Marcenaro E., Schneider P., Romero P., Jandus C. et al., 2021/02/08. eLife, 10 pp. e58838. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1C654EDB478E]
2020
 
Quantitative and qualitative impairments in dendritic cell subsets of patients with ovarian or prostate cancer.
Mastelic-Gavillet B., Sarivalasis A., Lozano L.E., Wyss T., Inoges S., de Vries IJM, Dartiguenave F., Jichlinski P., Derrè L., Coukos G. et al., 2020/06/23. European journal of cancer, 135 pp. 173-182. Peer-reviewed.
[DOI][Pmid][serval:BIB_2DED61B64BB4]
 
Intramuscular Immunization Induces Antigen-specific Antibodies in Urine.
Derré L., Lucca I., Cesson V., Valerio M., Cerantola Y., Burruni R., Fritschi U., Gharbi D., Bobst M., Legris A.S. et al., 2020/03/15. European urology focus, 6 (2) pp. 280-283. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_278D1CCE5A4E]
Disulfide-Linked Peptides for Blocking BTLA/HVEM Binding.
Spodzieja M., Kuncewicz K., Sieradzan A., Karczyńska A., Iwaszkiewicz J., Cesson V., Węgrzyn K., Zhukov I., Maszota-Zieleniak M., Michielin O. et al., 2020/01/18. International journal of molecular sciences, 21 (2). Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A28A31EE871C]
2019
Adenosine mediates functional and metabolic suppression of peripheral and tumor-infiltrating CD8<sup>+</sup> T cells.
Mastelic-Gavillet B., Navarro Rodrigo B., Décombaz L., Wang H., Ercolano G., Ahmed R., Lozano L.E., Ianaro A., Derré L., Valerio M. et al., 2019/10/10. Journal for immunotherapy of cancer, 7 (1) p. 257. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_CC3C085DEA43]
 
The multifaceted immune regulation of bladder cancer.
Schneider A.K., Chevalier M.F., Derré L., 2019/10. Nature reviews. Urology, 16 (10) pp. 613-630. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_84C0FB4F0070]
Intravesical Ty21a Vaccine Promotes Dendritic Cells and T Cell-Mediated Tumor Regression in the MB49 Bladder Cancer Model.
Domingos-Pereira S., Sathiyanadan K., La Rosa S., Polák L., Chevalier M.F., Martel P., Hojeij R., Derré L., Haefliger J.A., Jichlinski P. et al., 2019/04. Cancer immunology research, 7 (4) pp. 621-629. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_2BADE2231C76]
 
The pro- and anti-tumor role of ILC2s.
Trabanelli S., Chevalier M.F., Derré L., Jandus C., 2019/02. Seminars in immunology, 41 p. 101276. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_ECAD6DCB8107]
A structural model of the immune checkpoint CD160-HVEM complex derived from HDX-mass spectrometry and molecular modeling.
Kuncewicz K., Spodzieja M., Sieradzan A., Karczyńska A., Dąbrowska K., Dadlez M., Speiser D.E., Derre L., Rodziewicz-Motowidło S., 2019/01/11. Oncotarget, 10 (4) pp. 536-550. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_F79CFFA532C9]
Double Positive CD4<sup>+</sup>CD8<sup>+</sup> T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization.
Bohner P., Chevalier M.F., Cesson V., Rodrigues-Dias S.C., Dartiguenave F., Burruni R., Tawadros T., Valerio M., Lucca I., Nardelli-Haefliger D. et al., 2019. Frontiers in immunology, 10 p. 622. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4BC4F69D1158]
2018
 
Conventional and PD-L1-expressing Regulatory T Cells are Enriched During BCG Therapy and may Limit its Efficacy.
Chevalier M.F., Schneider A.K., Cesson V., Dartiguenave F., Lucca I., Jichlinski P., Nardelli-Haefliger D., Derré L., 2018/11. European urology, 74 (5) pp. 540-544. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_09E73A101B01]
 
Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.
Rentsch C.A., Derré L., Dugas S.G., Wetterauer C., Federer-Gsponer J.R., Thalmann G.N., Ingersoll M.A., 2018/07. European urology focus, 4 (4) pp. 485-493. Peer-reviewed.
[DOI][Pmid][serval:BIB_B4DB908A37EA]
Sensitive and frequent identification of high avidity neo-epitope specific CD8 + T cells in immunotherapy-naive ovarian cancer.
Bobisse S., Genolet R., Roberti A., Tanyi J.L., Racle J., Stevenson B.J., Iseli C., Michel A., Le Bitoux M.A., Guillaume P. et al., 2018/03/15. Nature communications, 9 (1) p. 1092. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_10AE95ADCEE8]
2017
Immunothérapie : une révolution dans la prise en charge du cancer de la vessie ? [Immunotherapy : a revolution in the management of urothelial bladder cancer ?]
Adam S.M., Derré L., Jichlinski P., Lucca I., 2017/11/29. Revue medicale suisse, 13 (585) pp. 2074-2078. Peer-reviewed.
[URN][Pmid][serval:BIB_2CC8F9CAC7B2]
Tumour-derived PGD2 and NKp30-B7H6 engagement drives an immunosuppressive ILC2-MDSC axis.
Trabanelli S., Chevalier M.F., Martinez-Usatorre A., Gomez-Cadena A., Salomé B., Lecciso M., Salvestrini V., Verdeil G., Racle J., Papayannidis C. et al., 2017/09/19. Nature communications, 8 (1) p. 593. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_40D92F523196]
Immunoregulation of Dendritic Cell Subsets by Inhibitory Receptors in Urothelial Cancer.
Chevalier M.F., Bohner P., Pieraerts C., Lhermitte B., Gourmaud J., Nobile A., Rotman S., Cesson V., Martin V., Legris A.S. et al., 2017/06. European urology, 71 (6) pp. 854-857. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_001B02D71DD0]
 
Intravesical Bacillus Calmette Guerin Combined with a Cancer Vaccine Increases Local T-Cell Responses in Non-muscle-Invasive Bladder Cancer Patients.
Derré L., Cesson V., Lucca I., Cerantola Y., Valerio M., Fritschi U., Vlamopoulos Y., Burruni R., Legris A.S., Dartiguenave F. et al., 2017/02/01. Clinical cancer research, 23 (3) pp. 717-725. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_7E871163C3ED]
Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
Spodzieja M., Lach S., Iwaszkiewicz J., Cesson V., Kalejta K., Olive D., Michielin O., Speiser D.E., Zoete V., Derré L. et al., 2017. PloS one, 12 (6) pp. e0179201.
[URN][DOI][WoS][Pmid][serval:BIB_8C02B51C71F2]
ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.
Chevalier M.F., Trabanelli S., Racle J., Salomé B., Cesson V., Gharbi D., Bohner P., Domingos-Pereira S., Dartiguenave F., Fritschi A.S. et al., 2017. The Journal of Clinical Investigation, 127 (8) pp. 2916-2929. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_FA350D3E0400]
 
Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer.
Domingos-Pereira S., Cesson V., Chevalier M.F., Derré L., Jichlinski P., Nardelli-Haefliger D., 2017. Oncoimmunology, 6 (1) pp. e1265720. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_1971614566E5]
2016
 
Le traitement standard du cancer de la vessie non musculo-invasif avec du BCG peut être associé à une vaccination anti-cancer pour augmenter la réponse vaccinale cellulaire T locale
Jichlinski P., Derré L., Nardell-Haefliger D., Speiser D., Romero P., 2016/11., Société française d'urologie p. 705 dans 110e Congrès français d'urologie, Progrès en Urologie.
[DOI][serval:BIB_22CC3EAF8590]
 
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope
Baumgaertner P., Costa Nunes C., Cachot A., Maby-El Hajjami H., Cagnon L., Braun M., Derré L., Rivals J.-P., Rimoldi D., Gnjatic S. et al., 2016/10/02. OncoImmunology, 5 (10) pp. e1216290.
[DOI][WoS][Pmid][serval:BIB_B9A2EC467477]
Targeting endothelial connexin40 inhibits tumor growth by reducing angiogenesis and improving vessel perfusion.
Alonso F., Domingos-Pereira S., Le Gal L., Derré L., Meda P., Jichlinski P., Nardelli-Haefliger D., Haefliger J.A., 2016/03/22. Oncotarget, 7 (12) pp. 14015-14028. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_42D2A2696272]
Immunogenic Human Papillomavirus Pseudovirus-Mediated Suicide-Gene Therapy for Bladder Cancer.
Hojeij R., Domingos-Pereira S., Nkosi M., Gharbi D., Derré L., Schiller J.T., Jichlinski P., Nardelli-Haefliger D., 2016/03/14. International journal of molecular sciences, 17 (7) pp. E1125. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_43FA35E9A155]
 
Analyse de l’infiltration immunitaire au cours des instillations intravésicales de BCG : identification d’un profil immunosuppressif prédictif de la récidive tumorale
Chevalier M., Trabanelli S., Gharbi D., Cesson V., Domingos-Pereira S., Dartiguenave F., Fritschi A., Speiser D., Romero P., Jandus C. et al., 2016., Société française d'urologie p. 707 dans 110e Congrès français d'urologie, Progres en urologie .
[DOI][serval:BIB_D847F7806040]
Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8(+) and CD4(+) T-cell responses with multiple specificities including a novel DR7-restricted epitope.
Baumgaertner P., Costa Nunes C., Cachot A., Maby-El Hajjami H., Cagnon L., Braun M., Derré L., Rivals J.P., Rimoldi D., Gnjatic S. et al., 2016. Oncoimmunology, 5 (10) pp. e1216290. Peer-reviewed.
[URN][DOI][Pmid][serval:BIB_A6A68301DF3E]
2015
 
High-throughput monitoring of human tumor-specific T-cell responses with large peptide pools.
Chevalier M.F., Bobisse S., Costa-Nunes C., Cesson V., Jichlinski P., Speiser D.E., Harari A., Coukos G., Romero P., Nardelli-Haefliger D. et al., 2015. Oncoimmunology, 4 (10) pp. e1029702. Peer-reviewed.
[DOI][Pmid][serval:BIB_FC441F50334F]
Local Salmonella immunostimulation recruits vaccine-specific CD8 T cells and increases regression of bladder tumor.
Domingos-Pereira S., Hojeij R., Reggi E., Derré L., Chevalier M.F., Romero P., Jichlinski P., Nardelli-Haefliger D., 2015. Oncoimmunology, 4 (7) pp. e1016697. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_4AEADA8DF103]
2014
Immunotherapeutic strategies for bladder cancer.
Chevalier M.F., Nardelli-Haefliger D., Domingos-Pereira S., Jichlinski P., Derré L., 2014. Human Vaccines and Immunotherapeutics, 10 (4) pp. 977-981. Peer-reviewed.
[URN][WoS][Pmid][serval:BIB_A25269F0E43E]
 
Intravaginal and subcutaneous immunization induced vaccine specific CD8 T cells and tumor regression in the bladder.
Domingos-Pereira S., Derré L., Warpelin-Decrausaz L., Haefliger J.A., Romero P., Jichlinski P., Nardelli-Haefliger D., 2014. Journal of Urology, 191 (3) pp. 814-822.
[URN][DOI][WoS][Pmid][serval:BIB_5CCCD4E4842E]
2013
CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses.
Corgnac S., Perret R., Derré L., Zhang L., Stirnemann K., Zauderer M., Speiser D.E., Mach J.P., Romero P., Donda A., 2013. Cancer Immunology, Immunotherapy, 62 (4) pp. 747-760.
[URN][DOI][WoS][Pmid][serval:BIB_ED058D025B50]
 
CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells.
Thibult M.L., Rivals J.P., Mamessier E., Gertner-Dardenne J., Pastor S., Speiser D.E., Derré L., Olive D., 2013. Journal of Molecular Medicine, 91 (2) pp. 195-205.
[URN][DOI][WoS][Pmid][serval:BIB_41EC0257E313]
Intravaginal live attenuated Salmonella increase local antitumor vaccine-specific CD8(+) T cells.
Decrausaz L., Pythoud C., Domingos-Pereira S., Derré L., Jichlinski P., Nardelli-Haefliger D., 2013. Oncoimmunology, 2 (1) pp. e22944.
[URN][DOI][WoS][Pmid][serval:BIB_5658EE1F539B]
2012
Detection of functional antigen-specific T cells from urine of non-muscle invasive bladder cancer patients.
Pieraerts C., Martin V., Jichlinski P., Nardelli-Haefliger D., Derre L., 2012. Oncoimmunology, 1 (5) pp. 694-698.
[URN][DOI][Pmid][serval:BIB_CFDAD27012D4]
Intravaginal TLR agonists increase local vaccine-specific CD8 T cells and human papillomavirus-associated genital-tumor regression in mice.
Domingos-Pereira S., Decrausaz L., Derré L., Bobst M., Romero P., Schiller J.T., Jichlinski P., Nardelli-Haefliger D., 2012. Mucosal Immunology, 6 (2) pp. 393-404.
[URN][DOI][WoS][Pmid][serval:BIB_688E4F5E989B]
The HVEM network: new directions in targeting novel costimulatory/co-inhibitory molecules for cancer therapy.
Pasero C., Speiser D.E., Derré L., Olive D., 2012. Current Opinion in Pharmacology, 12 (4) pp. 478-485.
[URN][DOI][WoS][Pmid][serval:BIB_673AC528840D]
Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells.
Baumgaertner P., Jandus C., Rivals J.P., Derré L., Lövgren T., Baitsch L., Guillaume P., Luescher I.F., Berthod G., Matter M. et al., 2012. International Journal of Cancer. Journal International Du Cancer, 130 (11) pp. 2607-2617.
[URN][DOI][WoS][Pmid][serval:BIB_6D78EF0CB662]
2011
TCRep 3D: an automated in silico approach to study the structural properties of TCR repertoires.
Leimgruber A., Ferber M., Irving M., Hussain-Kahn H., Wieckowski S., Derré L., Rufer N., Zoete V., Michielin O., 2011. PLoS One, 6 (10) pp. e26301.
[URN][DOI][WoS][Pmid][serval:BIB_A31DB21BDF3C]
2010
BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.
Derré L., Rivals J.P., Jandus C., Pastor S., Rimoldi D., Romero P., Michielin O., Olive D., Speiser D.E., 2010. Journal of Clinical Investigation, 120 (1) pp. 157-167.
[URN][DOI][WoS][Pmid][serval:BIB_D0FCA4850407]
Quantitative multiparameter assays to measure the effect of adjuvants on human antigen-specific CD8 T-cell responses.
Derré L., Jandus C., Baumgaertner P., Posevitz V., Devêvre E., Romero P., Speiser D.E., 2010. Methods in Molecular Biology, 626 pp. 231-249.
[URN][DOI][WoS][Pmid][serval:BIB_F8A15042C403]
2009
 
Dominant human CD8 T cell clonotypes persist simultaneously as memory and effector cells in memory phase.
Touvrey C., Derré L., Devevre E., Corthesy P., Romero P., Rufer N., Speiser D.E., 2009. Journal of Immunology, 182 (11) pp. 6718-6726. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D53CB51E794F]
Increased frequency of nonconventional double positive CD4CD8 alphabeta T cells in human breast pleural effusions.
Desfrançois J., Derré L., Corvaisier M., Le Mével B., Catros V., Jotereau F., Gervois N., 2009. International Journal of Cancer, 125 (2) pp. 374-380.
[DOI][WoS][Pmid][serval:BIB_8C9E478C625B]
Tumor antigen-specific FOXP3+ CD4 T cells identified in human metastatic melanoma: peptide vaccination results in selective expansion of Th1-like counterparts.
Jandus C., Bioley G., Dojcinovic D., Derré L., Baitsch L., Wieckowski S., Rufer N., Kwok W.W., Tiercy J.M., Luescher I.F. et al., 2009. Cancer Research, 69 (20) pp. 8085-8093. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_13A6AAC3E36C]
2008
Distinct sets of alphabeta TCRs confer similar recognition of tumor antigen NY-ESO-1157-165 by interacting with its central Met/Trp residues.
Derré L., Bruyninx M., Baumgaertner P., Ferber M., Schmid D., Leimgruber A., Zoete V., Romero P., Michielin O., Speiser D.E. et al., 2008. Proceedings of the National Academy of Sciences of the United States of America, 105 (39) pp. 15010-15015. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_9C31B2F8BC85]
2007
A novel population of human melanoma-specific CD8 T cells recognizes Melan-AMART-1 immunodominant nonapeptide but not the corresponding decapeptide.
Derré L., Ferber M., Touvrey C., Devevre E., Zoete V., Leimgruber A., Romero P., Michielin O., Lévy F., Speiser D.E., 2007. Journal of Immunology, 179 (11) pp. 7635-7645.
[URN][DOI][WoS][Pmid][serval:BIB_C81EFE777B85]
IL-12 controls cytotoxicity of a novel subset of self-antigen-specific human CD28+ cytolytic T cells.
Barbey C., Baumgaertner P., Devevre E., Rubio-Godoy V., Derre L., Bricard G., Guillaume P., Luescher I.F., Liénard D., Cerottini J.C. et al., 2007. Journal of Immunology, 178 (6) pp. 3566-3574. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_34A31269CA86]
In Vivo Persistence of Codominant Human CD8+ T Cell Clonotypes Is Not Limited by Replicative Senescence or Functional Alteration.
Derré L., Bruyninx M., Baumgaertner P., Devevre E., Corthesy P., Touvrey C., Mahnke Y.D., Pircher H., Voelter V., Romero P. et al., 2007. Journal of Immunology, 179 (4) pp. 2368-2379. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_96E2EC572F21]
2006
Ex vivo detectable human CD8 T-cell responses to cancer-testis antigens.
Baumgaertner P., Rufer N., Devevre E., Derre L., Rimoldi D., Geldhof C., Voelter V., Liénard D., Romero P., Speiser D.E., 2006. Cancer Research, 66 (4) pp. 1912-1916. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_D9CFEA5BF1AA]
Expression and release of HLA-E by melanoma cells and melanocytes: potential impact on the response of cytotoxic effector cells.
Derré L., Corvaisier M., Charreau B., Moreau A., Godefroy E., Moreau-Aubry A., Jotereau F., Gervois N., 2006. Journal of Immunology, 177 (5) pp. 3100-3107.
[DOI][WoS][Pmid][serval:BIB_14A82096D8CE]
2004
 
Inducible Hsp70 as target of anticancer immunotherapy: Identification of HLA-A*0201-restricted epitopes.
Faure O., Graff-Dubois S., Bretaudeau L., Derré L., Gross D.A., Alves P.M., Cornet S., Duffour M.T., Chouaib S., Miconnet I. et al., 2004. International Journal of Cancer, 108 (6) pp. 863-870.
[DOI][WoS][Pmid][serval:BIB_02B4C064F3C8]
2003
Identification of five new HLA-B*3501-restricted epitopes derived from common melanoma-associated antigens, spontaneously recognized by tumor-infiltrating lymphocytes.
Benlalam H., Linard B., Guilloux Y., Moreau-Aubry A., Derré L., Diez E., Dreno B., Jotereau F., Labarrière N., 2003. Journal of Immunology, 171 (11) pp. 6283-6289.
[DOI][WoS][Pmid][serval:BIB_B8FF502638B1]
2002
Expression of CD94/NKG2-A on human T lymphocytes is induced by IL-12: implications for adoptive immunotherapy.
Derre L., Corvaisier M., Pandolfino M.C., Diez E., Jotereau F., Gervois N., 2002. Journal of Immunology, 168 (10) pp. 4864-4870.
[DOI][WoS][Pmid][serval:BIB_D4FD8DDB104F]
2001
Comprehensive analysis of the frequency of recognition of melanoma-associated antigen (MAA) by CD8 melanoma infiltrating lymphocytes (TIL): implications for immunotherapy.
Benlalam H., Labarrière N., Linard B., Derré L., Diez E., Pandolfino M.C., Bonneville M., Jotereau F., 2001. European Journal of Immunology, 31 (7) pp. 2007-2015.
[DOI][WoS][Pmid][serval:BIB_8B409ACE0230]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University